Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Shares Outstanding (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Shares Outstanding for 13 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding changed 0.0% year-over-year to $2.8 million, compared with a TTM value of $2.8 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $2.8 million, changed 0.0% over the prior year.
  • Shares Outstanding was $15.4 million for Q4 2025 at Fate Therapeutics, up from $2.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $114.6 million in Q1 2025 and bottomed at $2.8 million in Q4 2024.
  • Average Shares Outstanding over 5 years is $42.2 million, with a median of $2.8 million recorded in 2021.
  • The sharpest move saw Shares Outstanding skyrocketed 3381.6% in 2022, then plummeted 97.2% in 2024.
  • Year by year, Shares Outstanding stood at $2.8 million in 2021, then surged by 3381.6% to $97.3 million in 2022, then crashed by 97.16% to $2.8 million in 2023, then fell by 0.22% to $2.8 million in 2024, then changed by 0.0% to $2.8 million in 2025.
  • Business Quant data shows Shares Outstanding for FATE at $2.8 million in Q4 2025, $2.8 million in Q3 2025, and $2.8 million in Q2 2025.